Abstract |
Plasma cell leukemia is a rare disease associated with very poor survival with standard treatment. We report a patient affected by plasma cell leukemia treated with aggressive chemotherapy and autologous CD34-selected PBPC who achieved a complete remission now lasting more than 2 years. Molecular studies confirmed the presence of minimal residual disease (MRD) despite the absence of disease activity. High-dose chemotherapy with stem cell rescue may be applied to selected patients considering the impact of the treatment on survival. The meaning of molecular MRD in this setting is unclear.
|
Authors | S Sica, P Chiusolo, P Salutari, N Piccirillo, L Laurenti, E Ortu La Barbera, F G Serra, G Leone |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 22
Issue 8
Pg. 823-5
(Oct 1998)
ISSN: 0268-3369 [Print] England |
PMID | 9827984
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Antigens, CD34
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Combined Modality Therapy
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Plasma Cell
(pathology, therapy)
- Middle Aged
- Neoplasm, Residual
- Remission Induction
- Time Factors
- Transplantation, Autologous
|